Table 3 Multivariant logistic regression analysis of non-DM PCSK9i-treated patients. Dependent variable: new-onset DM (compared with baseline characteristics)
From: Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
OR | CI 95% | sig | |
|---|---|---|---|
Fasting glucose | 1.1 | 1-1.3 | 0.027 |
BMI | 1 | 0.9–1.2 | 0.773 |
Statin | 1.5 | 0.7–35.1 | 0.791 |
Ezetimibe | 2.4 | 0.1–40.6 | 0.531 |
Age | 1 | 0.9–1.1 | 0.642 |
Male sex | 1.4 | 0.2–9.9 | 0.731 |
Alirocumab | 1 | 0.03–31.6 | 0.995 |
LDL-C reduction at 1y | 1 | 0.9-1 | 0.590 |
FH | 2.4 | 0.1–45.1 | 0.565 |
Treatment duration (months) | 1 | 1-1.1 | 0.313 |